BR112023023420A2 - Compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativas - Google Patents
Compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativasInfo
- Publication number
- BR112023023420A2 BR112023023420A2 BR112023023420A BR112023023420A BR112023023420A2 BR 112023023420 A2 BR112023023420 A2 BR 112023023420A2 BR 112023023420 A BR112023023420 A BR 112023023420A BR 112023023420 A BR112023023420 A BR 112023023420A BR 112023023420 A2 BR112023023420 A2 BR 112023023420A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- carboxylic acid
- acid group
- neurodegenerative diseases
- compounds
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- -1 AZETIDINYL COMPOUNDS Chemical class 0.000 title 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativas. a presente invenção refere-se a compostos e composições dos mesmos para a modulação de s1p5. em algumas modalidades, os compostos e composições são fornecidos para o tratamento de doenças neurológicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211313P | 2021-06-16 | 2021-06-16 | |
| PCT/US2022/033523 WO2022266162A1 (en) | 2021-06-16 | 2022-06-15 | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023420A2 true BR112023023420A2 (pt) | 2024-01-30 |
Family
ID=82595041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023420A BR112023023420A2 (pt) | 2021-06-16 | 2022-06-15 | Compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11919879B2 (pt) |
| EP (1) | EP4355729A1 (pt) |
| JP (1) | JP2024522718A (pt) |
| KR (1) | KR20240021883A (pt) |
| CN (1) | CN117500785A (pt) |
| AR (1) | AR126159A1 (pt) |
| AU (1) | AU2022291768A1 (pt) |
| BR (1) | BR112023023420A2 (pt) |
| CA (1) | CA3217423A1 (pt) |
| IL (1) | IL308122A (pt) |
| MX (1) | MX2023014197A (pt) |
| TW (1) | TW202317534A (pt) |
| WO (1) | WO2022266162A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024129948A1 (en) * | 2022-12-16 | 2024-06-20 | Celgene Corporation | Heterocyclic compounds as modulators of s1p5 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO167087C (no) | 1985-10-25 | 1991-10-02 | Secr Defence Brit | Fremgangsmaate for fremstilling av en nitratester. |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| JPH11512386A (ja) | 1995-09-01 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | ４−８員複素環へのｃ−ｃ結合を有するフェニルオキサゾリジノン |
| WO2000005214A2 (en) | 1998-07-24 | 2000-02-03 | Pfizer Inc. | Isoquinolines as urokinase inhibitors |
| WO2003018549A2 (en) | 2001-08-30 | 2003-03-06 | Chemocentryx, Inc. | Bicyclic compounds as inhibitors of chemokine binding to us28 |
| KR20050025345A (ko) | 2002-07-12 | 2005-03-14 | 아벤티스 파마 도이칠란트 게엠베하 | 헤테로사이클릭으로 치환된 벤조일우레아, 이들의제조방법 및 약제로서 이의 용도 |
| EP1581509B1 (en) | 2002-12-20 | 2011-01-19 | Merck Sharp & Dohme Corp. | 1-(amino)indanes as edg receptor agonists |
| WO2004056800A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| KR20090087013A (ko) | 2006-10-30 | 2009-08-14 | 크로마 데러퓨릭스 리미티드 | 히스톤 탈아세틸효소의 억제제로서 히드록사메이트 |
| US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| WO2010056788A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| CN102388048B (zh) | 2009-02-10 | 2014-07-30 | 阿斯利康(瑞典)有限公司 | 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途 |
| WO2011036889A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| MX2012013130A (es) | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| AU2011253143A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
| WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| JP6049866B2 (ja) | 2012-05-09 | 2016-12-21 | ゾエティス・サービシーズ・エルエルシー | 駆虫剤としてのアゼチジン誘導体 |
| TW201408652A (zh) | 2012-07-11 | 2014-03-01 | Hoffmann La Roche | 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物 |
| EA201590953A1 (ru) | 2012-11-16 | 2015-08-31 | Бристол-Майерс Сквибб Компани | Пирролидиновые модуляторы gpr40 |
| WO2015055771A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| EA035499B1 (ru) | 2014-01-06 | 2020-06-25 | Ризен Фармасьютикалз Са | Новые ингибиторы глутаминазы |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| ES2674531T3 (es) | 2014-05-07 | 2018-07-02 | Bristol-Myers Squibb Company | Moduladores del receptor acoplado a la proteína g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes |
| WO2016040225A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators |
| US11219625B2 (en) | 2015-07-24 | 2022-01-11 | Yale University | Inhibitors of N-linked glycosylation and methods using same |
| CA3001666C (en) | 2015-10-12 | 2021-03-30 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| EP3409658B9 (en) * | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
| WO2017156165A1 (en) | 2016-03-09 | 2017-09-14 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| WO2017205425A1 (en) | 2016-05-24 | 2017-11-30 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| CN109311849B (zh) | 2016-06-13 | 2021-02-26 | 吉利德科学公司 | 调节fxr(nr1h4)的化合物 |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| EP3585775B1 (en) | 2017-02-21 | 2022-04-06 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| AU2018312836B2 (en) | 2017-08-07 | 2022-12-08 | Joint Stock Company "Biocad" | Novel heterocyclic compounds as CDK8/19 inhibitors |
| WO2019141803A1 (en) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| WO2020035540A1 (en) | 2018-08-16 | 2020-02-20 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
| WO2020071550A1 (ja) | 2018-10-04 | 2020-04-09 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
| CA3115830C (en) | 2018-10-30 | 2023-09-12 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| CN111484479B (zh) | 2019-01-25 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 |
| KR20220027991A (ko) | 2019-07-03 | 2022-03-08 | 에프. 호프만-라 로슈 아게 | 헤테로시클릭 모노아실글리세롤 리파아제(magl) 억제제 |
| AU2020334489A1 (en) | 2019-08-20 | 2022-03-03 | Ono Pharmaceutical Co., Ltd. | Salt and crystal form of compound having agonistic activity to S1P5 receptor |
| CN111704613B (zh) | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
| WO2022140555A1 (en) | 2020-12-23 | 2022-06-30 | Celgene Corporation | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases |
-
2022
- 2022-06-15 BR BR112023023420A patent/BR112023023420A2/pt unknown
- 2022-06-15 CN CN202280042673.6A patent/CN117500785A/zh active Pending
- 2022-06-15 AU AU2022291768A patent/AU2022291768A1/en active Pending
- 2022-06-15 AR ARP220101582A patent/AR126159A1/es unknown
- 2022-06-15 WO PCT/US2022/033523 patent/WO2022266162A1/en active Application Filing
- 2022-06-15 CA CA3217423A patent/CA3217423A1/en active Pending
- 2022-06-15 IL IL308122A patent/IL308122A/en unknown
- 2022-06-15 KR KR1020247001145A patent/KR20240021883A/ko unknown
- 2022-06-15 TW TW111122266A patent/TW202317534A/zh unknown
- 2022-06-15 MX MX2023014197A patent/MX2023014197A/es unknown
- 2022-06-15 JP JP2023577349A patent/JP2024522718A/ja active Pending
- 2022-06-15 EP EP22743647.4A patent/EP4355729A1/en active Pending
- 2022-06-15 US US17/840,876 patent/US11919879B2/en active Active
-
2024
- 2024-01-25 US US18/422,500 patent/US20240270714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230028747A1 (en) | 2023-01-26 |
| US20240270714A1 (en) | 2024-08-15 |
| JP2024522718A (ja) | 2024-06-21 |
| AU2022291768A1 (en) | 2023-11-30 |
| US11919879B2 (en) | 2024-03-05 |
| CN117500785A (zh) | 2024-02-02 |
| WO2022266162A1 (en) | 2022-12-22 |
| KR20240021883A (ko) | 2024-02-19 |
| IL308122A (en) | 2023-12-01 |
| EP4355729A1 (en) | 2024-04-24 |
| MX2023014197A (es) | 2024-01-18 |
| AR126159A1 (es) | 2023-09-27 |
| TW202317534A (zh) | 2023-05-01 |
| CA3217423A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007157A (es) | Heteroarilamidas utiles como inhibidores de kif18a. | |
| CU20210029A7 (es) | Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades | |
| CR20210387A (es) | Inhibidores de kif18a | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| MX2021007158A (es) | Heteroarilamidas utiles como inhibidores de kif18a. | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| MX2022001181A (es) | Inhibidores de kif18a. | |
| BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| MX2018010374A (es) | Inhibidores del enlace proteína-proteína de wdr5. | |
| BR112017009647A2 (pt) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer | |
| BR112015021999A8 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase | |
| BRPI0518222A (pt) | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos | |
| EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
| BR112022019991A2 (pt) | Compostos, composição farmacêutica compreendendo o mesmo, e usos dos mesmos | |
| CO2021015264A2 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| BR112022015110A2 (pt) | Compostos e usos dos mesmos | |
| BR112023023425A2 (pt) | Compostos heterocíclicos substituídos | |
| MX2020002399A (es) | Inhibidores del enlace proteína-proteína de wdr5. | |
| BR112022012473A2 (pt) | Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo | |
| BR112022005757A2 (pt) | Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma | |
| EA202091396A1 (ru) | Композиции и способы лечения метаболических состояний | |
| BR112023025358A2 (pt) | Inibidores de protease como antivirais | |
| BR112023023420A2 (pt) | Compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativas |